Final overall survival (OS) analysis of COU-AA-302, a randomized phase 3 study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (MCRPC) patients (pts) without prior chemotherapy Meeting Abstract
| Authors: | Ryan, C. J.; Smith, M. R.; Fizazi, K.; Miller, K.; Mulders, P.; Sternberg, C. N.; Saad, F.; Griffin, T.; De Porre, P.; Park, Y. C.; Li, J.; Kheoh, T.; Naini, V.; Molina, A.; Rathkopf, D. E. |
| Abstract Title: | Final overall survival (OS) analysis of COU-AA-302, a randomized phase 3 study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (MCRPC) patients (pts) without prior chemotherapy |
| Meeting Title: | 39th ESMO Congress (ESMO 2014) |
| Journal Title: | Annals of Oncology |
| Volume: | 25 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2014 Sep 26-30 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2014-09-01 |
| Start Page: | iv255 |
| Language: | English |
| ACCESSION: | WOS:000346901000242 |
| DOI: | 10.1093/annonc/mdu336.1 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 753O -- Source: Wos |
